Vaccine therapy in early HIV-1 infection using a recombinant canarypox virus expressing gp160(MN) (ALVAC-HIV): A double-blind controlled randomized study of safety and immunogenicity

被引：0
|
作者：
Tubiana, R
Gomard, E
Fleury, H
Gougeon, ML
Mouthon, B
Picolet, H
Katlama, C
机构：
[1] HOP COCHIN,INSERM,U445,F-75674 PARIS,FRANCE
[2] VIROL LAB,BORDEAUX,FRANCE
[3] PASTEUR MERIEUX SERUMS & VACCINS,LYON,FRANCE
[4] INST PASTEUR,PARIS,FRANCE
来源：
AIDS | 1997年 / 11卷 / 06期
关键词：
D O I：
暂无
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
引用
收藏
页码：819 / 820
页数：2
相关论文
共 50 条
  • [21] Cytokine responses to human immunodeficiency virus type I (HIV-1) induced by immunization with live recombinant canarypox virus vaccine expressing HIV-1 genes boosted by HIV-1SF-2 recombinant GP120
    Gorse, GJ
    Patel, GB
    Mandava, MD
    Arbuckle, JA
    Doyle, TM
    Belshe, RB
    VACCINE, 2001, 19 (13-14) : 1806 - 1819
  • [22] Safety and Immunogenicity of a Randomized Phase 1 Prime-Boost Trial With ALVAC-HIV (vCP205) and Oligomeric Glycoprotein 160 From HIV-1 Strains MN and LAI-2 Adjuvanted in Alum or Polyphosphazene
    O'Connell, Robert J.
    Excler, Jean-Louis
    Polonis, Victoria R.
    Ratto-Kim, Silvia
    Cox, Josephine
    Jagodzinski, Linda L.
    Liu, Michelle
    Wieczorek, Lindsay
    McNeil, John G.
    El-Habib, Raphaelle
    Michael, Nelson L.
    Gilliam, Bruce L.
    Paris, Robert
    VanCott, Thomas C.
    Tomaras, Georgia D.
    Birx, Deborah L.
    Robb, Merlin L.
    Kim, Jerome H.
    JOURNAL OF INFECTIOUS DISEASES, 2016, 213 (12): : 1946 - 1954
  • [23] A PRIME-BOOST APPROACH TO HIV PREVENTIVE VACCINE USING A RECOMBINANT CANARYPOX VIRUS EXPRESSING GLYCOPROTEIN 160 (MN) FOLLOWED BY A RECOMBINANT GLYCOPROTEIN 160 (MN/LAI) (VOL 11, PG 373, 1995)
    PIALOUX, G
    AIDS RESEARCH AND HUMAN RETROVIRUSES, 1995, 11 (07) : 875 - 875
  • [24] Safety and immunogenicity of an adjuvanted protein therapeutic HIV-1 vaccine in subjects with HIV-1 infection: A randomised placebo-controlled study
    Harrer, Thomas
    Plettenberg, Andreas
    Arasteh, Keikawus
    Van Lunzen, Jan
    Faetkenheuer, Gerd
    Jaeger, Hans
    Janssens, Michel
    Burny, Wivine
    Collard, Alix
    Roman, Francois
    Loeliger, Alfred
    Koutsoukos, Marguerite
    Bourguignon, Patricia
    Lavreys, Ludo
    Voss, Gerald
    VACCINE, 2014, 32 (22) : 2657 - 2665
  • [25] Dendritic Cell Immunotherapy for HIV-1 Infection Using Autologous HIV-1 RNA: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial
    Jacobson, Jeffrey M.
    Routy, Jean-Pierre
    Welles, Seth
    DeBenedette, Mark
    Tcherepanova, Irina
    Angel, Jonathan B.
    Asmuth, David M.
    Stein, David K.
    Baril, Jean-Guy
    McKellar, Mehri
    Margolis, David M.
    Trottier, Benoit
    Wood, Kenneth
    Nicolette, Charles
    JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2016, 72 (01) : 31 - 38
  • [26] Immunogenicity of LC16m8Δ Vaccinia Virus/Sendai Virus Vector Expressing the Gp160 of HIV-1 and Effect of CD40Lm
    Shida, H.
    AIDS RESEARCH AND HUMAN RETROVIRUSES, 2011, 27 (10) : A107 - A107
  • [27] Phase I study of a candidate vaccine based on recombinant HIV-1 gp160 (MN/LAI) administered by the mucosal route to HIV-seronegative volunteers:: The ANRS VAC14 study
    Pialoux, Gilles
    Hocini, Hakim
    Perusat, Sophie
    Silberman, Benjamin
    Salmon-Ceron, Dominique
    Slama, Laurence
    Journot, Valerie
    Mathieu, Emmanuelle
    Gaillard, Christophe
    Petitprez, Karine
    Launay, Odile
    Chene, Genevieve
    VACCINE, 2008, 26 (21) : 2657 - 2666
  • [28] SAFETY AND IMMUNOGENICITY OF A FULLY GLYCOSYLATED RECOMBINANT GP160 HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 VACCINE IN SUBJECTS AT LOW-RISK OF INFECTION
    BELSHE, RB
    CLEMENTS, ML
    DOLIN, R
    GRAHAM, BS
    MCELRATH, J
    GORSE, GJ
    SCHWARTZ, D
    KEEFER, MC
    WRIGHT, P
    COREY, L
    BOLOGNESI, DP
    MATTHEWS, TJ
    STABLEIN, DM
    OBRIEN, FS
    EIBL, M
    DORNER, F
    KOFF, W
    JOURNAL OF INFECTIOUS DISEASES, 1993, 168 (06): : 1387 - 1395
  • [29] Enhanced Immune Responses to HIV-1 Envelope Elicited by a Vaccine Regimen Consisting of Priming with Newcastle Disease Virus Expressing HIV gp160 and Boosting with gp120 and SOSIP gp140 Proteins
    Khattar, Sunil K.
    DeVico, Anthony L.
    LaBranche, Celia C.
    Panda, Aruna
    Montefiori, David C.
    Samal, Siba K.
    JOURNAL OF VIROLOGY, 2016, 90 (03) : 1682 - 1686
  • [30] Randomized controlled trial of the efficacy of a recombinant canarypox HIV-1 vaccine in IV drug users: A phase 3 study in Boston, MA
    Dhalla, S
    AMERICAN JOURNAL OF EPIDEMIOLOGY, 2003, 157 (11) : S95 - S95
12345